TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) yesterday said that it expects rapid revenue growth next year after it receives approval to sell an injectable formulation of its novel antibiotic in China.
The company hopes that Taigexyn (nemonoxacin) will follow the same path in China as Bayer AG’s moxifloxacin, as the German pharmaceutical giant saw rapid sales growth after an injectable formulation was introduced to the market.
“Patients in China simply prefer the needle, as they think it is far more potent and effective than oral formulations,” TaiGen Asia chief commercial officer Philip Huang (黃國龍) told an investors’ conference in Taipei, adding that injectables make up 85.5 percent of China’s annual antibiotic sales.
While the oral formulation of Taigexyn received marketing approval from the China Food and Drug Administration in 2016, the company has yet to see significant growth from the drug, as it is still building its brand and networks of hospitals and physicians, he said.
The oral formulation would help make Taigexyn a known name among patients and physicians as the company awaits approval for the injectable formulation, Huang said, adding that unit sales of the antibiotic surged 562.7 percent in the first nine months of this year, with unit sales in the past quarter alone skyrocketing 651.1 percent.
In February, the injectable formulation was granted fast-track designation by Chinese regulators, saving it from a long line to be reviewed that would have added two to three years to the approval process, he said.
Chinese regulators have begun inspecting clinical trial data and the company expects the intravenous formulation to receive marketing approval before the end of next year, he added.
Bayer’s moxifloxacin sales first exceeded 100 million yuan (US$14.4 million at the current exchange rate) in 2005, one year after its intravenous formulation was approved, Huang said.
Since then, moxifloxacin sales had jumped to 1.89 billion yuan as of the end of last year, with its injectable formulation contributing 1.44 billion yuan, he said.
Moxifloxacin has maintained robust growth, despite the emergence of two Chinese-developed generic and biosimilar injectables, Huang added.
“As China’s income levels and medical insurance coverage continue to rise, the overall market will continue to grow for all drugmakers,” Huang said.
TaiGen said it has also been gearing up to submit a new drug application to regulators in the US and China for its next-generation antiviral, which is designed to block replication and transmission of the influenza A and B viruses.
TECH RACE: The Chinese firm showed off its new Mate XT hours after the latest iPhone launch, but its price tag and limited supply could be drawbacks China’s Huawei Technologies Co (華為) yesterday unveiled the world’s first tri-foldable phone, as it seeks to expand its lead in the world’s biggest smartphone market and steal the spotlight from Apple Inc hours after it debuted a new iPhone. The Chinese tech giant showed off its new Mate XT, which users can fold three ways like an accordion screen door, during a launch ceremony in Shenzhen. The Mate XT comes in red and black and has a 10.2-inch display screen. At 3.6mm thick, it is the world’s slimmest foldable smartphone, Huawei said. The company’s Web site showed that it has garnered more than
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
Vanguard International Semiconductor Corp (世界先進) and Episil Technologies Inc (漢磊) yesterday announced plans to jointly build an 8-inch fab to produce silicon carbide (SiC) chips through an equity acquisition deal. SiC chips offer higher efficiency and lower energy loss than pure silicon chips, and they are able to operate at higher temperatures. They have become crucial to the development of electric vehicles, artificial intelligence data centers, green energy storage and industrial devices. Vanguard, a contract chipmaker focused on making power management chips and driver ICs for displays, is to acquire a 13 percent stake in Episil for NT$2.48 billion (US$77.1 million).
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
RSS